Eton Pharmaceutcials
ETON
164 hedge funds and large institutions have $723M invested in Eton Pharmaceutcials in 2026 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 57 increasing their positions, 36 reducing their positions, and 5 closing their positions.
980% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 5
65% more capital invested
Capital invested by funds: $439M → $723M (+$284M)
58% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 36
41% more funds holding
Funds holding: 116 → 164 (+48)
18% more call options, than puts
Call options by funds: $4.85M | Put options by funds: $4.1M
7.7% more ownership
Funds ownership: 65.18% → 72.89% (+7.7%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$9.32M |
| 2 |
Morgan Stanley
New York
|
+$8.5M |
| 3 |
D.E. Shaw & Co
New York
|
+$5.53M |
| 4 |
BlackRock
New York
|
+$5.24M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell Capital
Alta,
Wyoming
|
-$5.02M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.11M |
| 3 |
Renaissance Technologies
New York
|
-$3.26M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$3.19M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.04M |
ETON Hedge Fund Activity: Q2 2026 in Review
164 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q2 2026, worth a combined $723M — up 65% from $439M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ETON positions and 5 closed out — a net gain of 49 holders — while 57 added to existing stakes and 36 trimmed.
The largest buyer was Nuveen, adding an estimated $9.32M. The largest seller was Cannell Capital, cutting an estimated $5.02M.
- 164 institutional investors held Eton Pharmaceutcials (ETON) as of Q2 2026, up from 116 in Q1 2026.
- Funds reported $723M of Eton Pharmaceutcials stock for Q2 2026, up 65% quarter-over-quarter.
- 54 funds opened new Eton Pharmaceutcials positions in Q2 2026 and 5 closed out, a net change of +49 holders.
- The largest Eton Pharmaceutcials buyer in Q2 2026 was Nuveen, an estimated $9.32M added.
- The largest Eton Pharmaceutcials seller in Q2 2026 was Cannell Capital, an estimated $5.02M sold.
Based on aggregated 13F filings for Q2 2026.